Overall, our findings demonstrate that systemic delivery of AAV-mxABE can rescue DMD gene expression, and support further exploration of this approach as a potential gene therapy to treat patients with DMD and other monogenic diseases. Here, DMD is linked to Duchenne muscular dystrophy.